Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2023 Earnings Call Transcript February 6, 2024 5:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O’Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Tyler Van Buren - TD Cowen Salveen Richter - Goldman Sachs Leon Wang - Barclays Terrence Fl ...

For the quarter ended December 2023, Gilead Sciences (GILD) reported revenue of $7.12 billion, down 3.7% over the same period last year. EPS came in at $1.72, compared to $1.67 in the year-ago quarter.The reported revenue represents a surprise of +0.51% over the Zacks Consensus Estimate of $7.08 billion. With the consensus EPS estimate being $1.76, the EPS surprise was -2.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...

Q4 & FY23 Financial Results February 6, 2024 Contents Q4 & FY23 Key Takeaways 4-6 Commercial Results 7-17 Pipeline Updates 18-24 Financial Results 25-31 Appendix 33-40 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval. About Gilead Scie ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of revenue growth for Gilead’s base business, driven by both HIV and Oncology,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “The strength of the business provides a solid foundation as we enter a new catalyst-rich phase for the company. We are expecting several milestones in 2024, including updat ...

Gilead Sciences Inc. (GILD) is set to report fourth-quarter 2023 results on Feb 6, after market close.The company has a mixed track record, with earnings beating estimates in two of the last four quarters and missing in the remaining two, the average negative surprise being 0.24%. In the last reported quarter, the company posted an earnings surprise of 19.9%.Factors to NoteRevenues in the fourth quarter have likely been boosted by growth in oncology and HIV franchise sales. However, a decline in Veklury (re ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors. Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup to a global c ...

Analysts on Wall Street project that Gilead Sciences (GILD) will announce quarterly earnings of $1.76 per share in its forthcoming report, representing an increase of 5.4% year over year. Revenues are projected to reach $7.08 billion, declining 4.2% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 1.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estim ...

Gilead Sciences (GILD) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 6, 2024, might help the stock move higher if these key numbers are better ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...